SQI Diagnostics Inc V.SQD.H

Healthcare Medical Devices

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.

TSXV:SQD.H - Post by User

SQI Diagnostics Inc > Earnings

<< Previous

Bullboard Posts

Next >>

Comment by mercedesmanon May 26, 2022 11:09pm

227 Views

Post# 34711074

RE:Earnings

ResearchGuy wrote: MM what's the verdict and your thoughts?

We now have Proof that a key revenue tap has been successfully turned on!

-quick ramp up of Revenues with a + $5m Q2 - check!

-good margin on sales - allowing for a quicker path to CF positive - check !

Delay in expected Q3 pop from Antibody tests in US (Tao #2) ..."The Company is actively pursuing a number of potential customers for this product approved by NYSDOH under CLIA."

Lets hope the momentum continues to accelerate in Q3 and Q4 resulting from taps #3 and # 4

Rali-DX sales
UHN lung transplants/assessments monetization.

Landing Antibody test partnerships will be important IMO. It will solve the marketing issue while leveraging existing databases of interested and qualified parties. And bring in US revenues.

Resurgence of Covid and the Flu in the fall will, in all likelihood (unfortunately for mankind, but fortunately for SQI) accelerate the flow of revenues from certain taps.

All in all, a good start . Revenues are finally there. Q over PY Q well set up going forward - a key element to the growth story

MM